Alzheimer's Disease Research

Alzheimer's disease (AD), the most common type of dementia, is an irreversible and progressive neurodegenerative disorder causing cognitive and functional impairment. It is characterized by formation of protein aggregates and progressive loss of neurons in the central nervous system (CNS). The symptoms of AD include short-term memory loss, confusion, irritability, aggression and mood swings, progressing to long-term memory deficit, withdrawal from social interactions and subsequently a loss in higher central functioning.

Alzheimer's Disease Research Products Targets

Products for Alzheimer's Disease Research - Page 23

Cat.No. Product Name Information/Activity
BCC7102 5-Iodo-A-85380, 5-trimethylstannyl N-BOC derivative 213766-21-3
BCC3821 Nicotine Difartrate 65-31-6
BCC6118 3-pyr-Cytisine 948027-43-8
BCC1902 RJR-2403 oxalate Rivanicline oxalate (RJR-2403 oxalate; (E)-Metanicotine oxalate) is a neuronal nicotinic receptor agonist, showing high selectivity for the α4β2 subtype (Ki=26 nM); > 1,000 fold selectivity than α7 receptors(Ki= 3.6 μM).
BCC7975 SIB 1508Y maleate 192231-16-6
BCC7469 TC 2559 difumarate 212332-35-9
BCN2170 Varenicline tartrate Varenicline Tartrate(CP 526555;Champix) is a nicotinic receptor partial agonist; it stimulates nicotine receptors more weakly than nicotine itself does.
BCC7341 Dihydro-β-erythroidine hydrobromide Dihydro-β-erythroidine (DHβE) hydrobromide is a potent, orally active and competitive antagonist of neuronal nicotinic acetyicholine receptors (nAChRs). Dihydro-β-erythroidine hydrobromide shows selectivity for α4β4 and α4β2 nAChRs, with IC50s of 0.19 and 0.37 μM, respectively. Antidepressant-like activities.
BCC7301 DMAB-anabaseine dihydrochloride 154149-38-9
BCC7651 Desformylflustrabromine hydrochloride Desformylflustrabromine hydrochloride is a selective agonist of α4β2 neuronal nicotinic acetylcholine receptor (nAChR) with a pEC50 of 6.48.